{"title":"Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis","link":"https://www.preprints.org/manuscript/202407.0402/v1","date":1720097449000,"content":"Background: The objective of this study was to evaluate, the clinical benefit of benralizumab in patients with uncontrolled severe asthma associated with chronic rhinosinusitis with nasal polyposis (CRSwNP).\nMethods: The study included patients with uncontrolled severe asthma associated with CRSwNP who started therapy with benralizumab. Pulmonary function, eosinophilia, IgE, comorbidity, changes in the Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Visual Analogue Scale (VAS), Quality of Life (AQLQ), VAS (obstruction, drip, anosmia, facial pressure), SNOT-22, decrease or withdrawal of steroids and other medication, hospital admissions and emergency visits were analysed. The FEOS scale and EXACTO were employed in the assessment of response.\nResults: We analyzed 58 patients who completed minimal treatment at 12 months. After treatment with benralizumab, exacerbations were reduced by 82% (p","author":"","siteTitle":"Preprints.org - The Multidisciplinary Preprint Platform","siteHash":"abac34b0506002eba4392ac15186820b9b5d7a0f2e5fce3a3511408258fb1a7e","entryHash":"158949a26c98759f5abea3439e516b604b9df950844ca36baea4af863a790218","category":"Interdisciplinary"}